Combined delivery and anti-cancer activity of paclitaxel and curcumin using polymeric micelles

Journal of Biomedical Nanotechnology

Volumn 11, Issue 4, 2015, Pages 578-589

  Gao, Xiang ^a   Wang, Bilan ^a   Wu, Qinjie ^a   Wei, Xiawei ^a   Zheng, Fengjin ^b   Men, Ke ^a   Shi, Huashan ^a   Huang, Ning ^b   Wei, Yuquan ^a   Gong, Changyang ^a  

^a SICHUAN UNIVERSITY   (China)

^b SICHUAN UNIVERSITY   (China)

Author keywords

Co delivery; Curcumin; Micelles; Paclitaxel; Self assembly

Indexed keywords

CELL DEATH; DISEASES; DRUG THERAPY; POLYMERS; SELF ASSEMBLY; TUMORS;

ANTI-ANGIOGENIC ACTIVITY; ANTI-TUMOR ACTIVITIES; ANTICANCER ACTIVITIES; CO DELIVERIES; CURCUMIN; INHIBITION OF TUMOR GROWTH; PACLITAXEL; POLY (EPSILONCAPROLACTONE);

MICELLES;

CURCUMIN; PACLITAXEL; ANTINEOPLASTIC AGENT; DRUG CARRIER; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MICELLE; POLYMER;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER THERAPY; COLON CANCER; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; EMBRYO; FEMALE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MICELLE; MOUSE; NONHUMAN; POLYMERIZATION; TUMOR CELL; TUMOR GROWTH; TUMOR MODEL; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; COLONIC NEOPLASMS; DRUG DELIVERY SYSTEM; FLUORESCENCE MICROSCOPY; HUMAN; METABOLISM; MICROCIRCULATION; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; ZEBRA FISH;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; COLONIC NEOPLASMS; CURCUMIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MICE; MICE, INBRED BALB C; MICELLES; MICROCIRCULATION; MICROSCOPY, FLUORESCENCE; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; PACLITAXEL; POLYMERS; ZEBRAFISH;

EID: 84918592447     PISSN: 15507033     EISSN: 15507041     Source Type: Journal    
DOI: 10.1166/jbn.2015.1964     Document Type: Article

References (30)

1. P. H. Maxwell, Tumor strengths and frailties: Aspiring to prevent colon cancer. Nat. Med. 18, 32 (2012).
2. G. N. Hortobagyi, Paclitaxel-based combination chemotherapy for breast cancer. Oncology 11, 943 (1997).
3. J. A. Bauer, A. B. Chakravarthy, J. M. Rosenbluth, D. Mi, E. H. Seeley, N. D. M. Granja-Ingram, M. G. Olivares, M. C. Kelley, I. A. Mayer, I. M. Meszoely, J. A. Means-Powell, K. N. Johnson, C. J. Tsai, G. D. Ayers, M. E. Sanders, R. J. Schneider, S. C. Formenti, R. M. Caprioli, and J. A. Pietenpol, Identification of markers of taxane sensitivity using proteomic and genomic analyses of breast tumors from patients receiving neoadjuvant paclitaxel and radiation. Clin. Cancer Res. 16, 681 (2010).
4. W. L. Allen, L. Stevenson, V. M. Coyle, P. V. Jithesh, I. Proutski, G. Carson, M. A. Gordon, H. D. Lenz, S. V. Schaeybroeck, D. B. Longley, and P. G. Johnston, A systems biology approach identifies SART1 as a novel determinant of both 5-fluorouracil and SN38 drug resistance in colorectal cancer. Mol. Cancer Ther. 11, 119 (2012).
5. J. P. Gillet, A. M. Calcagno, S. Varma, M. Marino, L. J. Green, M. I. Vora, C. Patel, J. N. Orina, T. A. Eliseeva, V. Singal, R. Padmanabhan, B. Davidson, R. Ganapathi, A. K. Sood, B. R. Rueda, S. V. Ambudkar, and M. M. Gottesman, Redefining the relevance of established cancer cell lines to the study of mechanisms of clinical anti-cancer drug resistance. P. Natl. Acad. Sci. USA 46, 18708 (2011).
6. R. Tiedt, E. Degenkolbe, P. Furet, B. A. Appleton, S. Wagner, J. Schoepfer, E. Buck, D. A. Ruddy, J. E. Monahan, M. D. Jones, J. Blank, D. Haasen, P. Drueckes, M. Wartmann, C. MaCarthy, W. R. Sellers, and F. Hofmann, A drug resistance screen using a selective MET inhibitor reveals a spectrum of mutations that partially overlap with activating mutations found in cancer patients. Cancer Res. 71, 5255 (2011).
7. H. J. Tsai, S. Kobayashi, K. Izawa, T. Ishida, T. Watanabe, K. Umezawa, S. F. Lin, and A. Tojo, Bioimaging analysis of nuclear factor-B activity in Philadelphia chromosome-positive acute lymphoblastic leukemia cells reveals its synergistic upregulation by tumor necrosis factor-α-stimulated changes to the microenvironment. Cancer Sci. 11, 2014 (2011).
8. K. Skak, M. Kragh, D. Hausman, M. J. Smyth, and P. V. Sivakumar, Interleukin 21: Combination strategies for cancer therapy. Nat. Rev. Drug Discov. 7, 231 (2008).
9. H. Wang, L. Hu, C. Li, J. Zhang, and T. Zhang, Increase of therapeutic activity of doxorubicin by long circulating liposomes in combination with curcumin. Die Pharm. Int. J. Pharm. Sci. 66, 871 (2011).
10. S. Bhattacharyya, D. Mandal, G. S. Sen, S. Pal, S. Banerjee, L. Lahiry, J. H. Finke, C. S. Tannenbaum, T. Das, and G. Sa, Tumor-induced oxidative stress perturbs nuclear factor-B activityaugmenting tumor necrosis factor-α-mediated T-cell death: Protection by curcumin. Cancer Res. 67, 362 (2007).
11. T. Golombick, T. H. Diamond, V. Badmaev, A. Manoharan, and R. Ramakrishna, The potential role of curcumin in patients with monoclonal gammopathy of undefined significance-Its effect on paraproteinemia and the urinary N-Telopeptide of type I collagen bone turnover marker. Clin. Cancer Res. 15, 5917 (2009).
12. M. A. Martinez-Paniagua, M. I. Vega, S. Huerta-Yepez, S. Baritaki, G. G. Vega, K. Harharan, and B. Bonavida, Galiximab signals B-NHL cells and inhibits the activities of NF-B-induced YY1-And Snail-resistant factors: Mechanism of sensitization to apoptosis by chemoimmunotherapeutic drugs. Mol. Cancer Ther. 11, 572 (2012).
13. X. Wu, J. Li, M. Zhu, J. A. Fletcher, and F. S. Hodi, Protein kinase C inhibitor AEB071 targets ocular melanoma harboring GNAQ mutations via effects on the PKC/Erk1/2 and PKC/NF-B pathways. Mol. Cancer Ther. 11, 1905 (2012).
14. J. Lu, M. Liong, J. I. Zink, and F. Tamanoi, Mesoporous silica nanoparticles as a delivery system for hydrophobic anticancer drugs. Small 3, 1341 (2007).
15. E. V. D. Steeg, A. V. Esch, E. Wagenaar, C. M. Kruijssen, O. V. Tellingen, K. E. Kenworthy, and A. H. Schinket, High impact of oatp1a/1b transporters on in vivo disposition of the hydrophobic anticancer drug paclitaxel. Clin. Cancer Res. 17, 294 (2011).
16. K. Shahani, S. K. Swaminathan, D. Freeman, A. Blum, L. Ma, and J. Panyam, Injectable sustained release microparticles of curcumin: A new concept for cancer chemoprevention. Cancer Res. 70, 4443 (2010).
17. V. Milacic, S. Banerjee, K. R. Landis-Piwowar, F. H. Sarkar, A. P. Majumdar, and Q. P. Dou, Curcumin inhibits the proteasome activity in human colon cancer cells in vitro and in vivo. Cancer Res. 68, 7283 (2008).
18. K. Xiao, Y. Li, J. S. Lee, A. M. Gonik, T. Dong, G. Fung, E. Sanchez, L. Xing, H. R. Cheng, J. Luo, and K. S. Lam, "OA02" peptide facilitates the precise targeting of paclitaxel-loaded micellar nanoparticles to ovarian cancer in vivo. Cancer Res. 72, 2100 (2012).
19. C. Y. Gong, Y. Xie, Q. J. Wu, Y. Wang, S. Deng, D. Xiong, L. Liu, M. Xiang, Z. Qian, and Y. Wei, Improving antitumor activity with polymeric micelles entrapping paclitaxel in pulmonary carcinoma. Nanoscale 4, 6004 (2012).
20. C. Gong, S. Deng, Q. Wu, M. Xiang, X. Wei, L. Li, X. Gao, B. Wang, L. Sun, Y. Chen, Y. Li, L. Liu, Z. Qian, and Y. Wei, Improving antiangiogenesis and anti-Tumor activity of curcumin by biodegradable polymeric micelles. Biomaterials 34, 1413 (2013).
21. Q. Wu, S. Deng, L. Li, L. Sun, X. Yang, X. Liu, L. Liu, Z. Qian, Y. Wei, and C. Gong, Biodegradable polymeric micelle-encapsulated quercetin suppresses tumor growth and metastasis in both transgenic zebrafish and mouse models. Nanoscale 5, 12480 (2013).
22. N. Patel, S. K. Chatterjee, V. Vrbanac, I. Chung, C. J. Mu, R. R. Olsen, C. Waghorne, and B. R. Zetter, Rescue of paclitaxel sensitivity by repression of Prohibitin1 in drug-resistant cancer cells. P. Natl. Acad. Sci. USA 6, 2503 (2010).
23. J. Hoffmann, M. Schirner, A. Menrad, and M. R. Schneider, A highly sensitive model for quantification of in vivo tumor angiogenesis induced by alginate-encapsulated tumor cells. Cancer Res. 57, 3847 (1997).
24. S. P. Herbert and D. Y. R. Stainier, Molecular control of endothelial cell behaviour during blood vessel morphogenesis. Nat. Rev. Mol. Cell Biol. 12, 551 (2011).
25. K. Kissa and P. Herbomel, Blood stem cells emerge from aortic endothelium by a novel type of cell transition. Nature 464, 112 (2010).
26. A. M. Kamat, S. T. Tharakan, B. Sung, and B. B. Aggarwal, Curcumin potentiates the antitumor effects of bacillus calmette-guerin against bladder cancer through the downregulation of NF-B and upregulation of TRAIL receptors. Cancer Res. 69, 8958 (2009).
27. X. B. Xiong and A. Lavasanifar, Traceable multifunctional micellar nanocarriers for cancer-Targeted co-delivery of MDR-1 siRNA and doxorubicin. ACS Nano 28, 5202 (2011).
28. A. L. Lee, Y. Wang, H. Y. Cheng, S. Pervaiz, and Y. Y. Yang, The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 30, 919 (2009).
29. L. Fan, F. Li, H. Zhang, Y. Wang, C. Cheng, X. Li, C. H. Gu, Q. Yang, H. Wu, and S. Zhang, Co-delivery of PDTC and doxorubicin by multifunctional micellar nanoparticles to achieve active targeted drug delivery and overcome multidrug resistance. Biomaterials 31, 5634 (2010).
30. H. Wang, Y. Zhao, Y. Wu, Y. L. Hu, K. Nan, G. Nie, and H. Chen, Enhanced anti-Tumor efficacy by co-delivery of doxorubicin and paclitaxel with amphiphilic methoxy PEG-PLGA copolymer nanoparticles. Biomaterials 32, 8281 (2011).